Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EPS (Basic) (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed EPS (Basic) for 14 consecutive years, with -$0.01 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) fell 150.0% year-over-year to -$0.01, compared with a TTM value of -$0.12 through Dec 2025, down 33.33%, and an annual FY2025 reading of -$0.12, down 33.33% over the prior year.
  • EPS (Basic) was -$0.01 for Q4 2025 at Heron Therapeutics, up from -$0.11 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.02 in Q4 2024 and bottomed at -$0.63 in Q1 2022.
  • Average EPS (Basic) over 5 years is -$0.25, with a median of -$0.15 recorded in 2023.
  • Peak annual rise in EPS (Basic) hit 200.0% in 2025, while the deepest fall reached 266.67% in 2025.
  • Year by year, EPS (Basic) stood at -$0.53 in 2021, then soared by 75.47% to -$0.13 in 2022, then surged by 61.54% to -$0.05 in 2023, then surged by 140.0% to $0.02 in 2024, then crashed by 150.0% to -$0.01 in 2025.
  • Business Quant data shows EPS (Basic) for HRTX at -$0.01 in Q4 2025, -$0.11 in Q3 2025, and -$0.02 in Q2 2025.